Efficacy, tolerability and safety of a range of doses of an orally inhaled, particle engineered, drug-only, suspension of glycopyrronium bromide in male and female patients with moderate or severe chronic obstructive pulmonary disease (COPD)

Authors
Category Primary study
JournalAmerican Journal of Respiratory and Critical Care Medicine
Year 2014
This article has no abstract
Epistemonikos ID: bf908595911e35b1ac0f9f421ecd11e90088eb45
First added on: Feb 07, 2025